Drugs / Tregopil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03430856 | Dec 2017 → Feb 2019 | type 2 diabetes mellitus | Biocon Limited | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04141423 Comparator | Oct 2019 → Apr 2021 | type 1 diabetes mellitus | Biocon Limited | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tregopil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03430856 ↗ |
| Known as | Insulin Tregopil | “This is an open label Phase II/III study to evaluate the efficacy and safety of test drug, Insulin Tregopil (IN-105) compared with Insulin Aspart (IAsp) in Type 2 Diabetes...” NCT03430856 ↗ |
| Modality | Protein / enzyme biologic | “Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled...” PMID 36352762 ↗ Nov 2022 |
| Route | Oral | “To be administered orally 10 ± 2 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit” NCT03430856 ↗ |